J Cerebrovasc Endovasc Neurosurg.  2012 Sep;14(3):148-156. 10.7461/jcen.2012.14.3.148.

Effect of Premedication Method and Drug Resistance of Antiplatelet Agent on Periprocedural Thromboembolic Events During Coil Embolization of an Unruptured Intracranial Aneurysm

• Park SH
• Kim YB
• Huh SK

• KMID: 1808448
• DOI: http://doi.org/10.7461/jcen.2012.14.3.148

Abstract

OBJECTIVE
A retrospective review of premedication method and drug resistance of aspirin and clopidogrel in association with thromboembolic events during and after coil embolization of an unruptured intracranial aneurysm was conducted.
METHODS
Our premedication policy for coil embolization of an unruptured intracranial aneurysm has changed from administration of the loading dose before the procedure (i.e. loading group) to repeated administration of the maintenance dose for several days (i.e. preparation group). The loading group (27 patients with 29 aneurysms) and the preparation group (30 patients with 35 aneurysms) were compared for identification of the effect of premedication method on periprocedural thromboembolic events. The results of drug response assays of the preparation group were analyzed with respect to periprocedural thromboembolic events.
RESULTS
No statistically significant difference in incidence of thromboembolic events was observed between the loading group and the preparation group. Analysis of the results of the drug response assay showed high prevalence (56.7%, 73.3%) of clopidogrel resistance and relatively low prevalence (6.7%) of aspirin resistance. Patients who had thromboembolic events tended to have lower responsiveness to both aspirin and clopidogrel than patients without it.
CONCLUSION
The method of antiplatelet premedication does not affect the rate of periprocedural thromboembolic events in coil embolization for treatment of an unruptured intracranial aneurysm. Nevertheless, considering the high prevalence of drug resistance, it is reasonable to premedicate antiplatelet agents in the preparation method for the drug response assay. Use of a higher dose of aspirin and clopidogrel or addition of an alternative drug (cilostazol or triflusal) can be applied against antiplatelet agent resistance. However, because the hemorrhagic risk associated with this supplementary use of antiplatelet agent has not been well-documented, the hemorrhagic risk and the preventive benefit must be weighed.

Keyword

Antiplatelet agent premedication; Aspirin resistance; Clopidogrel resistance; Thromboembolic complication

MeSH Terms

Aspirin
Drug Resistance
Humans
Incidence
Intracranial Aneurysm
Platelet Aggregation Inhibitors
Premedication
Prevalence
Retrospective Studies
Ticlopidine
Aspirin
Platelet Aggregation Inhibitors
Ticlopidine

Reference

1. Benitez RP, Silva MT, Klem J, Veznedaroglu E, Rosenwasser RH. Endovascular occlusion of wide-necked aneurysms with a new intracranial microstent (Neuroform) and detachable coils. Neurosurgery. 2004; 6. 54(6):1359–1367. discussion 1368. PMID: 15157292.

2. Coleman JL, Alberts MJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol. 2006; 9. 98(6):838–841. PMID: 16950199.

3. Fiorella D, Thiabolt L, Albuquerque FC, Deshmukh VR, McDougall CG, Rasmussen PA. Antiplatelet therapy in neuroendovascular therapeutics. Neurosurg Clin N Am. 2005; 7. 16(3):517–540. PMID: 15990042.

4. Fiorella D. Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel. J Neurointerv Surg. 2010; 3. 2(1):44–49. PMID: 21990558.

5. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008; 5. 51(19):1829–1843. PMID: 18466797.

6. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 8. 88(3):230–235. PMID: 11472699.

7. Hwang G, Jung C, Park SQ, Kang HS, Lee SH, Oh CW, et al. Thromboembolic complications of elective coil embolization of unruptured aneurysms: the effect of oral antiplatelet preparation on periprocedural thromboembolic complication. Neurosurgery. 2010; 9. 67(3):743–748. discussion 748. PMID: 20651627.

8. Jin EZ, Yu LH, Li XQ. Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention. Int Heart J. 2012; 53(1):1–4. PMID: 22398668.

9. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol. 2009; 3. 53(13):1101–1109. PMID: 19324253.

10. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv. 2010; 2. 3(1):17–26. PMID: 20118150.

11. Kang HS, Kwon BJ, Kim JE, Han MH. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol. 2010; 8. 31(7):1206–1210. PMID: 20223886.

12. Kim HK, Hwang SK, Kim SH. Types of thromboembolic complications in coil embolization for intracerebral aneurysms and management. J Korean Neurosurg Soc. 2009; 9. 46(3):226–231. PMID: 19844623.

13. Layton KF, Cloft HJ, Gray LA, Lewis DA, Kallmes DF. Balloon-assisted coiling of intracranial aneurysms: evaluation of local thrombus formation and symptomatic thromboembolic complications. AJNR Am J Neuroradiol. 2007; Jun-Jul. 28(6):1172–1175. PMID: 17569982.

14. Lee HW, Lim MS, Seong SJ, Lee J, Park J, Seo JJ, et al. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Expert Opin Drug Metab Toxicol. 2011; 12. 7(12):1471–1479. PMID: 22098139.

15. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl. 2005; 12. 6(4):33–40. PMID: 16275125.

16. Matsumoto Y, Kondo R, Matsumori Y, Shimizu H, Takahashi A, Tominaga T. Antiplatelet therapy for prevention of thromboembolic complications associated with coil embolization of unruptured cerebral aneurysms. Drugs R D. 2012; 3. 12(1):1–7. PMID: 22242721.

17. Meves SH, Neubauer H, Overbeck U, Endres HG. Is there an ideal way to initiate antiplatelet therapy with aspirin? A crossover study on healthy volunteers evaluating different dosing schemes with whole blood aggregometry. BMC Res Notes. 2011; 4. 4:106. PMID: 21466682.

18. Murdoch D, Plosker GL. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drugs. 2006; 66(5):671–692. PMID: 16620146.

19. Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res. 2008; 123(2):267–273. PMID: 18499236.

20. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005; 4. 111(16):2099–2106. PMID: 15750189.

21. Ryu DS, Hong CK, Sim YS, Kim CH, Jung JY, Joo JY. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc. 2010; 10. 48(4):319–324. PMID: 21113358.

22. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999; 25(Suppl 2):15–19. PMID: 10440417.

23. Suh JW, Kim SY, Park JS, Kim YS, Kang HJ, Koo BK, et al. Comparison of triple antiplatelet therapy including triflusal and conventional dual therapy in patients who underwent drug-eluting stent implantation. Int Heart J. 2009; 11. 50(6):701–709. PMID: 19952467.

24. Tourmousoglou CE, Rokkas CK. Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence. Cardiovasc Hematol Agents Med Chem. 2008; 10. 6(4):312–322. PMID: 18855644.

25. Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. Cardiovasc Ther. 2011; 12. 29(6):e100–e111. PMID: 21883990.

26. van Rooij WJ, Sluzewski M. Procedural morbidity and mortality of elective coil treatment of unruptured intracranial aneurysms. AJNR Am J Neuroradiol. 2006; 9. 27(8):1678–1680. PMID: 16971613.

27. Workman MJ, Cloft HJ, Tong FC, Dion JE, Jensen ME, Marx WF, et al. Thrombus formation at the neck of cerebral aneurysms during treatment with Guglielmi detachable coils. AJNR Am J Neuroradiol. 2002; 10. 23(9):1568–1576. PMID: 12372750.